Date: 2015-04-15
Type of information: Private placement
Company: uniqure (The Netherlands)
Investors:
Amount: $82.4 million (€76.5 million)
Funding type: follow-on public offering
Planned used:
Others: * On April 15, 2015, uniQure announced the closing of its previously announced follow-on public offering of 3,000,000 ordinary shares at an offering price of $29.50 per ordinary share. In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the offering price, less underwriting discounts. * On April 9, 2015, uniQure announced the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $ 29.50 per ordinary share. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the follow-on public offering are expected to be approximately $82.4 million (€76.5 million). In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. The offering is expected to close on or about April 15, 2015. * On April 7, 2015, uniQure announced that it has commenced a follow-on public offering of 3,000,000 of its ordinary shares. All ordinary shares to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Leerink Partners LLC, Cowen and Company, LLC, and Piper Jaffray & Co. are acting as the joint book-running managers for the offering. Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC are acting as co-managers.
Therapeutic area: Genetic diseases - Rare diseases
